Brought to you by 
Bristol signs clinical trial collaboration with PsiOxus
02 Sep 2016
Executive Summary
Bristol-Myers Squibb Co. formed an alliance to test the safety, tolerability, and preliminary efficacy of a combination of its Opdivo (nivolumab) with PsiOxus Therapeutics Ltd.'s enadenotucirev in Phase I studies for multiple tumors at later stages.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
- Trial Collaborations
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com